BERLIN, Aug. 14, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) reported financial results for the first six months ended June 30, 2007 and also confirmed the completed filing of its Marketing Authorization Application (MAA) for Icatibant in the treatment of hereditary angioedema (HAE) to the European Medicines Evaluation Agency (EMEA). In addition, the EMEA has granted Jerini accelerated assessment, which shortens the regulatory review period from 210 to 150 days and is granted to drug candidates addressing major public health interest and therapeutic innovation.
